EpiCast Report: Hodgkin S Lymphoma Epidemiology Forecast to 2024 Now Available at iData Insights EpiCast Report: Hodgkin s Lymphoma - Epidemiology Forecast to 2024 Summary Hodgkin s lymphoma (HL), also known as Hodgkin s disease, is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, which spreads beyond the lymphatic system and impairs the body s immune system. According to the American Cancer Society (ACS), HL can start anywhere in the lymphoid tissue of body, but quite often starts in the upper part of body with main sites in the neck, the chest, or under the arms. HL mostly spreads through lymph vessels to other lymph nodes, and in advanced stages can even invade the bloodstream and spread to other organs including the liver, lungs, and bone marrow. The most common symptoms of HL include enlarged lymph nodes under the skin of the neck, under the arm, or in the groin, fever (which can come and go over several days or weeks) without an infection; drenching night sweats, and weight loss. To forecast the diagnosed incident cases and five-year diagnosed prevalent cases of HL in 7MM, GlobalData epidemiologists obtained data from population-based studies that provided country-specific data in each of the 7MM. In addition, GlobalData epidemiologists used the staging system for HL known as the Cotswold system, which is a modification of the older Ann Arbor system, to segment the diagnosed incident cases of HL in the 7MM into stages I, II, III, and IV. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of HL in the 7MM from 23,662 diagnosed incident cases in 2014 to 28,397 diagnosed incident cases in 2024 at an Annual Growth Rate (AGR) of 2%. The increase in the diagnosed incident cases of HL was partly attributed to the moderately rising trend in the incidence of HL in the 7MM, combined with changes in the population demographics in the respective markets. Scope - The Hodgkin s Lymphoma (HL) EpiCast Report provides an overview of the risk factors and global trends of HL in the 7MM (US, France, Germany, Italy, Spain, UK and Japan). It includes a 10-year epidemiology forecast for the diagnosed incident cases of HL, segmented by age, sex, and clinical stage at diagnosis, and types (classical HL and nodular lymphocyte predominant HL, with classical HL further segmented into subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) in these markets. In addition, GlobalData epidemiologists provide a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HL, as well as the number of HL diagnosed incident cases refractory to chemo- and radiation therapy, the number of HL diagnosed incident cases who received autologous stem cell transplantation (ASCT), and HL diagnosed incident cases refractory to ASCT from 2014-2024 in these markets. - The HL epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Reasons to buy The Hodgkin s Lymphoma (HL) EpiCast series will allow you to - - Develop business strategies by understanding the trends shaping and driving the global HL market. - Quantify patient populations in the global HL market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HL therapeutics in each of the markets covered. - Identify the percentage of HL diagnosed incident cases by type and treatment. Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicastreport-dry-eye-syndrome-epidemiology-forecast-to-2024 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicastreport-dry-eye-syndrome-epidemiology-forecast-to-2024 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 9 2.3 Upcoming Related Reports
1
10 3 Epidemiology 11 3.1 Disease Background 11 3.2 Risk Factors and Comorbidities 12 3.3 Global Trends 14 3.3.1 Incidence 14 3.3.2 Survival Rates for HL
7MM
16 3.4 Forecast Methodology 17 3.4.1 Sources Used 21 3.4.2 Sources Not Used 23 3.4.3 Forecast Assumptions and Methods, HL Diagnosed Incident Cases 24 3.4.4 Forecast Assumptions and Methods, HL Five-Year Diagnosed Prevalent Cases 24 3.4.5 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis 25 3.4.6 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Cellular Types 26 3.4.7 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to CRT % 7MM 27 3.4.8 Forecast Assumptions and Methods, HL Diagnosed Incident Cases Who Received ASCT 27 3.4.9 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to ASCT 28 3.5 Epidemiological Forecast for HL (2014-2024) 29 3.5.1 Diagnosed Incident Cases of HL 29 3.5.2 Age-Specific Diagnosed Incident Cases of HL 30 3.5.3 Sex-Specific Diagnosed Incident Cases of HL 32 3.5.4 Age-Standardized Diagnosed Incidence of HL 34 3.5.5 Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis 35 3.5.6 Diagnosed Incident Cases of HL by Cellular Types 36 3.5.7 Diagnosed Incident Cases of HL, Refractory/Relapse to CRT 37 3.5.8 Diagnosed Incident Cases of HL, Receiving ASCT 38 3.5.9 Diagnosed Incident Cases of HL, Refractory to ASCT 39 3.5.10 Five-Year Diagnosed Prevalent Cases of HL 40 3.6 Discussion 42 3.6.1 Epidemiological Forecast Insight 42 3.6.2 Limitations of the Analysis 42 3.6.3 Strengths of the Analysis 43 4 Appendix 44 4.1 Bibliography 44 4.2 About the Authors
2
47 4.2.1 Epidemiologist 47 4.2.2 Reviewers 47 4.2.3 Global Director of Therapy Analysis and Epidemiology 48 4.2.4 Global Head of Healthcare 49 4.3 About GlobalData 50 4.4 About EpiCast 50 4.5 Disclaimer Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicast-report-dry-eye-syndromeepidemiology-forecast-to-2024 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
3